-
公开(公告)号：KR100520495B1
公开(公告)日：2005-10-11
申请号：KR1020020064986
申请日：2002-10-23
Applicant: 한국과학기술연구원
IPC: C07K16/18
Abstract: 본 발명은 베타아밀로이드의 형태를 특이적(specific)으로 인식하는 단일 클론 항체에 관한 것으로서, 상기 항체는 1) 베타아밀로이드 및 상기 베타아밀로이드를 안정한 형태(conformation)로 변형시키는 화합물로 구성된 혼합물을 제조하여 항원으로 사용하고 2) 상기 혼합물을 면역화하는 단계로 제조되는 것이다. 본 발명에 의한 항체는 종래에 베타아밀로이드 단독 또는 단순한 길이의 변화를 조절하여 항원으로 사용하여 제조한 항체에 비하여, 베타아밀로이드-화합물과의 혼합물을 사용하여 가장 안정된 형태의 베타아밀로이드 단위체를 강력하게 인식하는 항체를 제조함으로써, 베타아밀로이드의 집적으로 유발되는 알쯔하이머 병의 치료제로 유용하다.
-
公开(公告)号：KR100464926B1
公开(公告)日：2005-01-05
申请号：KR1020010056800
申请日：2001-09-14
Applicant: 한국과학기술연구원
IPC: C07K16/18
Abstract: PURPOSE: Antibodies specifically binding to the N-terminal of HIV gp 41 are provided, thereby function of gp41 which is essential for the infection of HIV can be inhibited, so that it can be useful for prevention and treatment of HIV. CONSTITUTION: The antibodies which are specifically binding to the N-terminal of HIV gp 41, are capable of recognizing gp 41-ex(extracellular domain), and inhibit function of gp 41 are provided, wherein the heavy chain of an antibody has the amino acid sequences of SEQ ID NO: 1 and the light chain of the antibody has the amino acid sequence of SEQ ID NO: 2; the heavy chain of an antibody has the amino acid sequences of SEQ ID NO: 3 and the light chain of the antibody has the amino acid sequence of SEQ ID NO: 4; the heavy chain of an antibody has the amino acid sequences of SEQ ID NO: 5 and the light chain of the antibody has the amino acid sequence of SEQ ID NO: 6; and the heavy chain of an antibody has the amino acid sequences of SEQ ID NO: 7 and the light chain of the antibody has the amino acid sequence of SEQ ID NO: 8.
Abstract translation: 目的：提供特异性结合于HIV gp41 N末端的抗体，从而可以抑制对HIV感染至关重要的gp41的功能，从而可用于HIV的预防和治疗。 构成：特异性结合于HIV gp 41 N末端的抗体能够识别gp 41-ex（胞外结构域），并且提供gp 41的抑制功能，其中抗体的重链具有氨基酸 SEQ ID NO：1的氨基酸序列和抗体的轻链具有SEQ ID NO：2的氨基酸序列; 抗体的重链具有SEQ ID NO：3的氨基酸序列，抗体的轻链具有SEQ ID NO：4的氨基酸序列; 抗体的重链具有SEQ ID NO：5的氨基酸序列，抗体的轻链具有SEQ ID NO：6的氨基酸序列; 并且抗体的重链具有SEQ ID NO：7的氨基酸序列，并且抗体的轻链具有SEQ ID NO：8的氨基酸序列。
-
公开(公告)号：KR1020030042632A
公开(公告)日：2003-06-02
申请号：KR1020010073358
申请日：2001-11-23
Applicant: 한국과학기술연구원
IPC: C07H15/232
CPC classification number: C07H5/10 , C07H15/232
Abstract: PURPOSE: Provided is a heterodimer of neomycin and chloramphenicol with improved specificity to a target RNA molecule to increase the medicinal efficacy while decreasing adverse effects due to the non-specific drugs. It is effectively used as an anti-virus agent, an anti-bacteria agent, or an anti-cancer agent. CONSTITUTION: A heterodimer(formula 1) of neomycin and chloramphenicol is structured such that the heterodimer is specific-coupled to 16S rRNA, RRE RNA, or TS RNA. In the formula(1), n is an integer of 2-10 and, more particularly, 3, 6 or 9. The specific coupling of the heterodimer to the RNA is characterized by simultaneously recognizing the stem and the loop of the RNA. The specific coupling is intrinsic to the sequence of RNA.
Abstract translation: 目的：提供新霉素和氯霉素的异二聚体，对目标RNA分子具有改进的特异性，以增加药物功效，同时减少由非特异性药物引起的不良反应。 它有效地用作抗病毒剂，抗菌剂或抗癌剂。 构成：新霉素和氯霉素的异二聚体（配方1）的结构使得异二聚体与16S rRNA，RRE RNA或TS RNA特异性偶联。 在式（1）中，n是2-10的整数，更特别是3-6或9.异源二聚体与RNA的特异性偶联特征在于同时识别RNA的茎和环。 特异性偶联是RNA序列固有的。
-
公开(公告)号：KR1020030024004A
公开(公告)日：2003-03-26
申请号：KR1020010056800
申请日：2001-09-14
Applicant: 한국과학기술연구원
IPC: C07K16/18
CPC classification number: C07K16/1045 , A61K39/21
Abstract: PURPOSE: Antibodies specifically binding to the N-terminal of HIV gp 41 are provided, thereby function of gp41 which is essential for the infection of HIV can be inhibited, so that it can be useful for prevention and treatment of HIV. CONSTITUTION: The antibodies which are specifically binding to the N-terminal of HIV gp 41, are capable of recognizing gp 41-ex(extracellular domain), and inhibit function of gp 41 are provided, wherein the heavy chain of an antibody has the amino acid sequences of SEQ ID NO: 1 and the light chain of the antibody has the amino acid sequence of SEQ ID NO: 2; the heavy chain of an antibody has the amino acid sequences of SEQ ID NO: 3 and the light chain of the antibody has the amino acid sequence of SEQ ID NO: 4; the heavy chain of an antibody has the amino acid sequences of SEQ ID NO: 5 and the light chain of the antibody has the amino acid sequence of SEQ ID NO: 6; and the heavy chain of an antibody has the amino acid sequences of SEQ ID NO: 7 and the light chain of the antibody has the amino acid sequence of SEQ ID NO: 8.
Abstract translation: 目的：提供与HIV gp 41的N-末端特异性结合的抗体，因此可以抑制对HIV感染必不可少的gp41的功能，因此可用于预防和治疗HIV。 构成：与HIV gp41的N-末端特异性结合的抗体能够识别gp 41-ex（细胞外结构域），并提供抑制gp41功能，其中抗体的重链具有氨基 SEQ ID NO：1的酸序列和抗体的轻链具有SEQ ID NO：2的氨基酸序列; 抗体的重链具有SEQ ID NO：3的氨基酸序列，抗体的轻链具有SEQ ID NO：4的氨基酸序列; 抗体的重链具有SEQ ID NO：5的氨基酸序列，抗体的轻链具有SEQ ID NO：6的氨基酸序列; 抗体的重链具有SEQ ID NO：7的氨基酸序列，抗体的轻链具有SEQ ID NO：8的氨基酸序列。
-
公开(公告)号：KR1020030012021A
公开(公告)日：2003-02-12
申请号：KR1020010045860
申请日：2001-07-30
Applicant: 한국과학기술연구원
IPC: C07K14/47
CPC classification number: C12N9/0036 , C07K14/47 , C07K2319/00
Abstract: PURPOSE: Provided are C-terminus protein of human nucleolar phosphoprotein hNopp140(hNOPP140) specifically binding with doxorubicin and the gene thereof. The C-terminus protein of hNopp140 acts on anticancer mechanism of doxorubicin in a living body, reduces toxicity of doxorubicin, and increases anticancer activity. CONSTITUTION: The hNopp140(hNOPP140) characteristically binds with doxorubicin and has amino acid sequence represented by the SEQ ID NO:1. Its coding gene has nucleotide sequence represented by the SEQ ID NO:2.
Abstract translation: 目的：提供与多柔比星及其基因特异性结合的人核仁磷酸蛋白hNopp140（hNOPP140）的C末端蛋白。 hNopp140的C末端蛋白作用于生物体中多柔比星的抗癌机制，降低多柔比星的毒性，增加抗癌活性。 构成：hNopp140（hNOPP140）特征性地与多柔比星结合并具有由SEQ ID NO：1表示的氨基酸序列。 其编码基因具有由SEQ ID NO：2表示的核苷酸序列。
-
Patent Agency Ranking
公开(公告)号：KR100347289B1
公开(公告)日：2002-08-07
申请号：KR1019990020954
申请日：1999-06-07
Applicant: 한국과학기술연구원
IPC: C07H21/02
Abstract: 본발명은암세포의시알릴루이스 X (sLeX)에높은특이성과친화성으로접합하는 RNA서열및 이를이용한 sLeX의탐지방법을제공한다. 시알릴루이스 X (sLeX)는염증과암의전이에관련된세포표면표적자이고, 본발명의선택된 RNA는그 접합강도나분자의특이성면에서우월한결과를가지므로, 이는암세포를특이적으로인식할수 있어암세포의탐지화및 암치료제의개발에획기적인결과를줄 수있는분자가될 수있는잠재력을가지고있다.
-
公开(公告)号：KR1020010076990A
公开(公告)日：2001-08-17
申请号：KR1020000004480
申请日：2000-01-29
Applicant: 한국과학기술연구원
IPC: C07K16/00
CPC classification number: C07K16/40 , C07K16/286 , C07K2317/56
Abstract: PURPOSE: An antibody for amino-RNA and a producing method thereof are provided, thereby the antibody can be easily produced, and it can be used in treatment of self-immunity disease. CONSTITUTION: The antibody for amino-RNA comprises VH of SEQ ID NO: 1 and VL of SEQ ID NO: 2, in which the amino-RNA specifically binds with a receptor of acetylcholine esterase. The method for producing the antibody for amino-RNA comprises the steps of: producing amino-RNA by substituting nucleotides of RNA during transcription from DNA of MG self-antibody to RNA; collecting a spleen from a mouse; carrying out in vitro immunization technique by incubating the spleen cells in a medium containing the amino-RNA for 3 days; fusing the immunized spleen cells with SP2/o-Ag14 and PEG1500; incubating them to produce hybridoma cells; and selecting hybridoma cells capable of producing antibody binding with amino-RNA.
Abstract translation: 目的：提供了用于氨基-RNA的抗体及其制备方法，由此能够容易地制备抗体，可以用于自身免疫性疾病的治疗。 构成：氨基-RNA抗体包含SEQ ID NO：1的VH和SEQ ID NO：2的VL，其中氨基-RNA与乙酰胆碱酯酶的受体特异性结合。 制备氨基-RNA抗体的方法包括以下步骤：通过在从MG自身的DNA转录到RNA的转录过程中用RNA取代RNA来产生氨基RNA; 从小鼠收集脾脏; 通过将脾细胞在含有氨基-RNA的培养基中培养3天进行体外免疫技术; 将免疫的脾细胞与SP2 / o-Ag14和PEG1500融合; 培养它们以产生杂交瘤细胞; 并选择能够产生与氨基-RNA结合的抗体的杂交瘤细胞。
-
公开(公告)号：KR1020010076898A
公开(公告)日：2001-08-17
申请号：KR1020000004317
申请日：2000-01-28
Applicant: 한국과학기술연구원
IPC: C12N15/00
Abstract: PURPOSE: RNA molecule conjugating with N-acethylneuramine-lactose is provided, which can be effectively used for the treatment of specific cancers or diseases followed by specific inflammation. CONSTITUTION: RNA molecule conjugating with N-acethylneuramine-lactose and having the base sequence of SEQ ID NO: 1 is isolated by the steps of: binding N-acethylneuramine lactose on the solid phase supporter by the covalent bond; binding RNA molecule with the N-acethylneuramine lactose fixed on the solid phase supporter; eluting the bound RNA library by using affinity chromatography; and repeating the steps to isolate RNA molecule strongly conjugating with N-acethylneuramine-lactose.
Abstract translation: 目的：提供与N-乙酰神经胺 - 乳糖共轭的RNA分子，可以有效地用于治疗特定的癌症或疾病，然后特异性炎症。 构成：通过以下步骤分离与N-乙酰甲基甘氨酸 - 乳糖共轭并具有SEQ ID NO：1的碱基序列的RNA分子，其通过共价键结合固相载体上的N-乙酰基三聚氰胺乳糖; 结合RNA分子与固定在固相载体上的N-乙酰基三聚氰胺乳糖; 通过亲和层析洗脱结合的RNA文库; 并重复步骤以分离与N-乙酰神经胺 - 乳糖强烈缀合的RNA分子。
-
公开(公告)号：KR1020010001606A
公开(公告)日：2001-01-05
申请号：KR1019990020953
申请日：1999-06-07
Applicant: 한국과학기술연구원
IPC: C07H21/02
Abstract: PURPOSE: Provided are an RNA sequence which has a binding specificity to kanamycin A and a selection method of the RNA sequence having a high specificity to an antibiotic such as kanamycin A. Because the RNA sequence is readily used in reverse drug discovery, it can cut costs and is useful in searching a novel target molecule to the kanamycin A. CONSTITUTION: The RNA is selected from the group consisting of SEQ ID NO : 1 - SEQ ID NO : 8 and has a binding specificity to kanamycin A. The RNA sequence is prepared by a 131 bp DNA sequence comprising 70 nucleotides of random sequence as shown in Fig. 1, wherein T7 RNA polymerase of 5'-primer promotes an in vitro transcription and the site of a restriction enzyme is useful in identifying that the inserts have been incorporated into the sequence. The selection method of the RNA sequence having a high specificity to the antibiotic comprises reacting the antibiotic fixed to solid phase with 100-200 bp of the RNA sequence ligated with 70 random nucleotides at 5' or 3' end thereof using a systematic evolution of ligand by exponential enrichment (SELEX) method.
Abstract translation: 目的：提供对卡那霉素A具有结合特异性的RNA序列和对抗生素如卡那霉素A具有高特异性的RNA序列的选择方法。因为RNA序列容易用于反向药物发现，因此可以切割 成本并且可用于在卡那霉素A中搜索新的靶分子。构成：RNA选自SEQ ID NO：1 - SEQ ID NO：8，并且对卡那霉素A具有结合特异性.RNA序列是 由包含70个核苷酸的随机序列的131bp DNA序列制备，如图1所示。 1，其中5'-引物的T7RNA聚合酶促进体外转录，并且限制酶的位点可用于鉴定插入片段已被并入序列。 对抗生素具有高特异性的RNA序列的选择方法包括将固定在固相上的抗生素与其5'或3'末端与70个随机核苷酸连接的DNA序列的100-200bp反应，使用配体的系统进化 通过指数富集（SELEX）方法。
-
公开(公告)号：KR100477326B1
公开(公告)日：2005-03-21
申请号：KR1020010020813
申请日：2001-04-18
Applicant: 한국과학기술연구원
IPC: C07K16/18
Abstract: 본 발명은 N-글리코시드 결합을 분해할 수 있는 촉매항체와 이를 코딩하는 DNA 분자를 제공하며, 당결합을 특이적으로 인식하고 절단할 수 있는 이러한 촉매항체는 여러 가지 복잡한 당분자를 쉽게 다룰 수 있는 수단이 되고, 인공 촉매의 기작에 관한 연구는 자연의 중요한 전이 반응 (transfer reaction)인 당의 형성과 분해과정에 작용하는 중요한 인자를 발견할 수 있는 기회를 제공해 줄 수 있으며, N-글리코시드 결합이 생체내의 중요한 대사경로에 관여하는 결합이라면 생체내의 치료제로서 사용할 수 있는 유용한 물질을 제공할 수 있다.
-
-
-
-
-
-
-
-
-
Search Results
43
records
(took 0.032 seconds)
